Top Scandion Oncology execs leave

31 August 2022
scandion-executive-management-large

Scandion Oncology (Nasdaq: SCOL), a Danish biotech developing medicines for treatment-resistant cancer, has announced that president and chief executive Bo Rode Hansen (pictured above, center) will leave his position with immediate effect by mutual agreement.

Johnny Stilou (pictured right), who has been Scandion's chief financial officer since July 2021, has been appointed acting CEO effective immediately, with the process to identify a new permanent boss having already started.

Search for permanent CEO underway

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology